Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02030067 · ClinicalTrials.gov registry record · Phase 1

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

A Phase 1 study of Solid Tumor and Metastatic Bladder Cancer, sponsored by Processa Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
127
Enrollment target
12
Study locations

NCT02030067 is a Phase 1 study of Solid Tumor and Metastatic Bladder Cancer that has completed, run by Processa Pharmaceuticals. The registered enrollment target is 127 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (43% lower). The trial reports 12 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02030067, a Phase 1 study of Solid Tumor and Metastatic Bladder Cancer, has completed, sponsored by Processa Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
127 participants
Enrollment target
12
Study locations

Study Summary

The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced bladder cancer).

Conditions Studied

Solid Tumor Metastatic Bladder Cancer

Interventions

  • DRUG RX-3117

Study Locations (12)

Florida

  • Rexahn Site - Miami
  • Rexahn Site - Miami Lakes

Alabama

  • Rexahn Site - Birmingham

Arizona

  • Rexahn Site - Tucson

California

  • Rexahn Site - Duarte

Illinois

  • Rexahn Site - Skokie

Missouri

  • Rexahn Site - St Louis

Nevada

  • Rexahn Site - Las Vegas

New York

  • Rexahn Site - New York

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2013-12
Est. Completion 2019-12
Phase Phase 1

Sponsor

Processa Pharmaceuticals

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02030067

The ClinicalTrials.gov registry entry for NCT02030067 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (43% lower). The listed sponsor is Processa Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which RX-3117 is the first listed.

NCT02030067 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Florida, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT02030067 about?

NCT02030067 is a clinical study titled "Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies". The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced ...

What is the current status of trial NCT02030067?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2013-12. Estimated completion is 2019-12.

What conditions does trial NCT02030067 study?

This clinical trial studies the following conditions: Solid Tumor, Metastatic Bladder Cancer.

What interventions are being tested in trial NCT02030067?

The interventions under investigation include: RX-3117 (DRUG).

Who is sponsoring clinical trial NCT02030067?

This trial is sponsored by Processa Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02030067 being conducted?

This trial has 12 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Metastatic Bladder Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.